drugset / Trial / NCT02498535

Efficacy and Safety of Inhaled Nitric Oxide (NO) in Cystic Fibrosis (CF) Patients

NCT02498535

RandomizedParallel-groupTriple-blindTreatment

Summary

Prospective, randomized, placebo controlled, phase II clinical study of subjects crossing over from an approved inhaled antibiotic to inhaled nitric oxide as compared to a placebo control arm.

Timeline

Start
2017-02-22
Primary completion
2020-06-01
Completion
2020-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Nitric Oxide Other / unclassified 160 ppm Inhaled

Indications